Kolexia
Romeo Clemence Oncologie médicale
Romeo Clemence
Oncologie médicale
Hcl - Site Centre Leon Berard
Lyon, France
50 Activités
161 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Carcinome épithélial de l'ovaire Carcinosarcome Hypersensibilité Tumeurs des cordons sexuels et du stroma gonadique Tumeurs du pancréas Tumeurs de l'utérus Carcinomes Maladies rares

Collaborateurs

Voir plus
Ray Isabelle
Ray Isabelle
Centre Léon-Bérard, Lyon, France
Arnaud-Coffin Patrick
Arnaud-Coffin Patrick
Hôpital Fleyriat, Bourg-en-Bresse, France
Laurent Marie
Laurent Marie
Centre Léon-Bérard, Lyon, France
Tredan Olivier
Tredan Olivier
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
B3TSI
28 collaboration(s)
Dernière en 2023
IQVIA
20 collaboration(s)
Dernière en 2023
M3 Global Research Ltd
7 collaboration(s)
Dernière en 2023
KANTAR PROFILES HEALTH
3 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
MYCA: Phase Ib / II Trial Evaluating the Association Myocet ® - Carboplatine in Patients Having a Cancer of the Ovary in Relapse, Sensitive to the Platinum
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
Gynecological carcinosarcomas: Overview and future perspectives.
Bulletin du cancer   05 septembre 2023
Rearrangement as a Diagnostic and Predictive Biomarker in Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Report of Four Cases.
JCO precision oncology   15 août 2023
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study.
Gynecologic oncology   19 mai 2023
Real-World Data on Newly Diagnosed -Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database.
Cancers   21 août 2022
Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network.
Cancers   12 janvier 2022
Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer.
Future oncology (London, England)   17 mars 2021
Rare ovarian tumors: an update on diagnosis and treatment.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society   26 mai 2020
Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
Current opinion in oncology   06 avril 2020
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.
Gynecologic oncology   14 novembre 2018